Literature DB >> 12539257

X-ray studies on ligands.

Jeffrey R Deschamps1, Judith L Flippen-Anderson, Clifford George.   

Abstract

Advances in x-ray crystallographic data collection, structure solution, and refinement/validation have reduced the time required and expanded the range of samples amenable to x-ray crystallographic studies. Consequently, we can now collect complete atomic resolution data sets on physically smaller crystals and solve larger problems by direct methods beyond what could have been accomplished even five years ago. Applying these improved methods to the study of opioid ligands has enhanced our knowledge of the opioid pharmacophore. Despite considerable progress, it is still difficult to define the pharmacophoric parameters required for highly selective and potent opioid peptides. In part this is due to the conformational flexibility remaining even in conformationally constrained peptides. Copyright 2003 Wiley Periodicals, Inc.

Mesh:

Substances:

Year:  2002        PMID: 12539257     DOI: 10.1002/bip.10308

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  3 in total

1.  Four-component pharmacophore model for endomorphins toward μ opioid receptor subtypes.

Authors:  Yng-Ching Wu; Tim Jaglinski; Jin-Yuan Hsieh; Jia-Jyun Chiu; Tzen-Yuh Chiang; Chi-Chuan Hwang
Journal:  J Mol Model       Date:  2011-05-27       Impact factor: 1.810

Review 2.  Conformationally constrained histidines in the design of peptidomimetics: strategies for the χ-space control.

Authors:  Azzurra Stefanucci; Francesco Pinnen; Federica Feliciani; Ivana Cacciatore; Gino Lucente; Adriano Mollica
Journal:  Int J Mol Sci       Date:  2011-05-03       Impact factor: 5.923

3.  Conformational heterogeneity of a leucine enkephalin analogue in aqueous solution and sodium dodecyl sulfate micelles: comparison of time-resolved FRET and molecular dynamics simulations.

Authors:  Jay R Unruh; Krzysztof Kuczera; Carey K Johnson
Journal:  J Phys Chem B       Date:  2009-10-29       Impact factor: 2.991

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.